Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Peptide Insurance Billing Reimbursement Guide 2026: Payer Category Comparison

Medicare Part B Yes. LMN + failed conventional therapy documentation FDA approval OR CMS-approved clinical trial (CED pathway) 15–30 business days 0–20% (most peptides denied under experimental exclusion) Medicare's NCD policies explicitly exclude non-FDA comp

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Medicare Part B
  • Yes. LMN + failed conventional therapy documentation
  • FDA approval OR CMS-approved clinical trial (CED pathway)
  • 15–30 business days
  • 0–20% (most peptides denied under experimental exclusion)
  • Medicare's NCD policies explicitly exclude non-FDA compounds unless enrolled in approved trials. Commercial peptides like GHRP 2 rarely qualify
  • Medicare Advantage (Part C)
  • Plan-specific. 60% of MA plans mirror Medicare NCDs, 40% apply commercial criteria
  • Varies by plan. Some accept Phase II RCTs, others require FDA approval
  • 10–21 business days
  • 15–40% if approved
  • MA plans with PBM partnerships (e.g., CVS Caremark, Express Scripts) may cover peptides excluded under traditional Medicare if clinical policy supports use
  • Commercial PPO/HMO
  • Yes. Medical necessity documentation required for J3490/J3590 codes
  • Phase II/III RCTs published in peer-reviewed journals within 10 years
  • 7–14 business days
  • 50–80% of submitted cost
  • Commercial plans offer the highest peptide approval rates when documentation includes specialty prescriber attestation and published dosing protocols
  • Self-Funded Employer Plans
  • Depends on employer PBM contract. May waive PA for certain peptides
  • Plan-specific. Some accept observational studies or institutional review board (IRB) approvals
  • 5–10 business days
  • 60–90% if formulary inclusion negotiated
  • Self-insured employers with innovative benefit designs may cover research peptides not approved by traditional payers. Verify plan's pharmacy benefit manual
  • Medicaid (State Plans)
  • State-dependent. 32 states require PA for all J-codes, 18 states exempt peptides under $500/month
  • State Medicaid formulary criteria. Most exclude non-FDA compounds unless approved under 1115 waiver
  • 14–45 business days
  • 10–30% (high denial rates across all states)
  • Medicaid peptide coverage remains the most restrictive. Claims succeed primarily in states with academic medical centre partnerships or rare disease waivers

Related resources

More comparisons